Skip to content

Citius Oncology, Inc. CTOR Merger-related charges and other

Merger-related charges and other at other companies

CTO
Citius Oncology, Inc.CTOR
$2.75M0.0%
SB Financial Group logo
SB Financial GroupSBFG
$700K0.0%
ROC
Rank One Computing ROC
$32.83K-11.6%
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX
$890.82K
KEE
Keel Infrastructure Corp. Common StockKEEL
$1.77M
Alto Ingredients, Inc. logo
Alto Ingredients, Inc.ALTO
-$115K-106%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-75.9%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NoncashMergerRelatedCosts.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s merger-related charges and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s merger-related charges and other?
Citius Oncology, Inc. (CTOR) reported merger-related charges and other of $2.75M in Q4 2025.
What does merger-related charges and other mean?
Includes non-cash expenses incurred during the integration of acquired businesses, such as asset write-downs or accounting adjustments. Identifying these costs allows investors to isolate core operating performance from the impact of one-time acquisition events.